The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Trial of an Intratumoral Injections of INXN-3001 in Subjects With Stage III or IV Melanoma
Official Title: Phase 1b' Open Label, Single Arm, Multicenter Trial to Evaluate the Safety, Tolerance, Response Rate and Immunological Effects of Repeated Intratumoral Injections of Adenoviral Transduced Autologous Dendritic Cells Engineered to Express hIL-12(INXN-3001) in Response to an Oral Activator Ligand in Patients With Unresectable Stage III C or IV Malignant Melanoma
Study ID: NCT00815607
Brief Summary: The purpose of this study is to test the safety of an investigational combination drug/immunotherapy for the treatment of Stage III/IV melanoma.
Detailed Description: This study will examine the effects of an oral Activator Ligand administration to modulate the timing of gene expression of human IL-12 by adenovirus-transduced dendritic cells injected into tumors.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
The Angeles Clinic and Research Institute, Santa Monica, California, United States
Helen F. Graham Cancer Center, Newark, Delaware, United States
• Nancy N. and J.C. Lewis Cancer Center & Research Pavilion at St. Joseph/Candles, Savannah, Georgia, United States
Oncology Specialists, S.C., Park Ridge, Illinois, United States
Goshen Clinic, Goshen, Indiana, United States
Billings Clinic, Billings, Montana, United States
Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
Mary Crowley Cancer Research Centers, Dallas, Texas, United States
Name: Andrew Marsh
Affiliation: Ziopharm Oncology
Role: STUDY_DIRECTOR